Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders

Forte, Alberto; Baldessarini, Ross J.; Tondo, Leonardo; Vázquez, Gustavo; Pompili, Maurizio; Girardi, Paolo

doi:10.1016/j.jad.2015.02.011

Cited by 164 publications

(126 citation statements)

References 69 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…Because the NAc plays a key role in the depression, it is of interest to study the role of sEH in the NAc. Many depressed patients become chronically ill, with several relapses (early return of symptoms within the expected duration of a current episode, of perhaps 3-12 mo) or later recurrences (new episodes) following initial short-term improvement or remission (55,56). Recurrence rates are over 85% within a decade of an index depressive episode, and average ∼50% or more within 6 mo of apparent clinical emission (56).…”

Section: Discussionmentioning

confidence: 99%

Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress

Ren

Ishima

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

134

156

View full text Add to dashboard Cite

Depression is a severe and chronic psychiatric disease, affecting 350 million subjects worldwide. Although multiple antidepressants have been used in the treatment of depressive symptoms, their beneficial effects are limited. The soluble epoxide hydrolase (sEH) plays a key role in the inflammation that is involved in depression. Thus, we examined here the role of sEH in depression. In both inflammation and social defeat stress models of depression, a potent sEH inhibitor, TPPU, displayed rapid antidepressant effects. Expression of sEH protein in the brain from chronically stressed (susceptible) mice was higher than of control mice. Furthermore, expression of sEH protein in postmortem brain samples of patients with psychiatric diseases, including depression, bipolar disorder, and schizophrenia, was higher than controls. This finding suggests that increased sEH levels might be involved in the pathogenesis of certain psychiatric diseases. In support of this hypothesis, pretreatment with TPPU prevented the onset of depression-like behaviors after inflammation or repeated social defeat stress. Moreover, sEH KO mice did not show depressionlike behavior after repeated social defeat stress, suggesting stress resilience. The sEH KO mice showed increased brain-derived neurotrophic factor (BDNF) and phosphorylation of its receptor TrkB in the prefrontal cortex, hippocampus, but not nucleus accumbens, suggesting that increased BDNF-TrkB signaling in the prefrontal cortex and hippocampus confer stress resilience. All of these findings suggest that sEH plays a key role in the pathophysiology of depression, and that epoxy fatty acids, their mimics, as well as sEH inhibitors could be potential therapeutic or prophylactic drugs for depression.brain-derived neurotrophic factor | depression | epoxyeicosatrienoic acid | soluble epoxide hydrolase | resilience

show abstract

Section: Discussionmentioning

confidence: 99%

Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress

Ren

Ishima

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

134

156

View full text Add to dashboard Cite

show abstract

“…Depression is characterized by a minimum of 2 weeks of depressed mood and/or anhedonia and at least four other symptoms that include changes in sleep, appetite/weight, energy, psychomotor activity, concentration, thought content (guilt and worthlessness), and suicidal intent. For many patients with BD, the depressive polarity is often more pervasive and more debilitating than manic states, with estimates that depressed mood accounts for up to two‐thirds of the time spent unwell, even with treatment 12, 223, 224. Subsyndromal depressive symptoms, which persist despite treatment, are particularly common and a major source of functional impairment in these patients 225, 226, 227, 228, 229.…”

Section: Acute Management Of Bipolar Depressionmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

“…Mental health services are increasingly adopting a strategy to diagnose and treat BD as early as possible [7,8], in order to prevent poor outcomes such as social and occupational disability and premature mortality from suicide and medical comorbidities [9][10][11]. However, the current approach to identify individuals at risk for BD, with an emphasis on clinical features, temperamental traits and family history, has insufficient predictive validity, with only a minority of 'at risk' individuals making the transition to BD [8,12,13].…”

Section: Introductionmentioning

confidence: 99%

Neural connectivity in youth at-risk for bipolar disorder: a review of functional magnetic resonance imaging studies

Santos¹,

Coroa²,

Caldeira³

et al. 2017

IJCNMH

View full text Add to dashboard Cite

Background: Delayed diagnosis of bipolar disorder (BD) is common in adolescents and young adults and the search for biomarkers to help in early diagnosis in BD at-risk populations is an important goal of neuroimaging research. Functional connectivity studies in BD patients suggests that anomalous connectivity between prefrontal and limbic regions could be risk biomarkers for BD. The aim of this review is to provide an overview of the neuroimaging literature that employed functional connectivity techniques in adolescents and young adults at-risk for BD.

show abstract

Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders

Cited by 164 publications

References 69 publications

Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress

Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Neural connectivity in youth at-risk for bipolar disorder: a review of functional magnetic resonance imaging studies

Contact Info

Product

Resources

About